Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

e," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the results of Savient's actions and efforts in support of its resubmission of the KRYSTEXXA™ (pegloticase)  BLA, the results of the reversion to and revalidation of the Phase 3 manufacturing process, whether the Company's third party contract manufacturing organization will successfully address the deficiencies and observations cited by the FDA at their facility, whether our BLA resubmission, combined with the submissions made and planned by our third party contract manufacturer, fully addresses the deficiencies and observations raised and provides the additional materials requested in the Complete Response Letter that we received from the FDA on July 31, 2009, which were further clarified in our meeting with the FDA on September 14, 2009, the timing of FDA action with respect to the resubmission, the efficacy and safety of KRYSTEXXA, potential FDA marketing approval for KRYSTEXXA and whether any further clinical trials will be required are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional cl
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/21/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced positive results from a randomized, double-blind Phase ... for the treatment of edematous fibrosclerotic panniculopathy (EFP), ... trial, all three doses of CCH (low (0.06mg), ... in the appearance of cellulite as measured by ...
(Date:8/20/2014)... The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 7,481 boxes of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ROSA, Calif. , Feb. 16 Osseon Therapeutics Inc. ... Europe . The procedures were performed in Milan, Italy . ... independent medical device distributor in Europe , Osseoplasty cases are ... United Kingdom , Germany and Spain . , ...
... N.J. , Feb. 16 IntegriChain, Inc., ... the launch of its new DNA: Dynamic NextGen ... helps pharmaceutical manufacturers unlock the value of Direct Data ... Data includes those data assets typically provided to ...
Cached Medicine Technology:Osseon Launches in Europe 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 3
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 ... products manufactured by Boston Scientific has begun in ... first bellwether trial. The Rottenstein Law Group LLP, ... women with claims of harm stemming from the ... a claim for compensation for injuries suffered at ...
(Date:8/21/2014)... 21, 2014 American Addiction Centers, a ... for individuals with drug and/or alcohol addiction, has been ... Growing Private Companies. , The company is ranked 7th ... list and 4th on the list in the “Nashville ... of 995%, American Addiction Centers (AAC) ascended to number ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 The ... family and product liability law, announces the launch of ... provides comprehensive information on morcellator surgery lawsuits ... 2014 FDA morcellator cancer warning and the July 2014 ... accompanying the April 17, 2014 FDA warning on morcellator ...
(Date:8/21/2014)... When children go back to school, they are ... to become sick and risk missing school. It is important ... fight these germs to ensure a successful school year. MedX ... with its XFactor program. , The XFactor program supports a ... ages 4 and up can receive 30-day supplies of chewable ...
(Date:8/21/2014)... 2014 Young girls with an intense, red, itchy ... increased risk of developing urinary tract infections (UTIs), according ... The treatment may be as simple as better hygiene ... swimming pools. , "Vulvitis is a common condition affecting ... Steve J. Hodges, M.D., associate professor of urology at ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:MedX Pharmacy Helps with Back to School Preparation 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2
... Gengraine Technologies (Avesthagen) has tied up //with Denmark's ... Fund for Developing Countries (IFU) for osteoporosis research. ... joint venture called Avesta Nordic Research Pvt. Ltd ... and the Danish research organization had invested the ...
... the University of Buffalo, has found that Post-menopausal// women has ... reported in the Journal of Periodontology, which was conducted in ... The results showed 57.5% of the women in the study ... cause of tooth loss in Post-menopausal women, as studies has ...
... population of 35 million of whom two million people// have ... from HIV infections an estimated 12% of the country’s children ... ,Tanzania has planned to provide free anti-retroviral drugs ... a period of five years. This year 44,000 patients in ...
... largest state of India, registers its win against polio as the ... the 1242 reported in the year 2002. , ,UNICEF, and ... of the country are leading the war against polio in India. ... around 1600 were from India alone, and 1242 cases were registered ...
... Club Worldwide, //an organization that supports cancer patients., ,According ... have cancer, or when their parents or siblings have the ... for support." , ,"Gilda's Club is one of those ... so I am very happy to make this gift to ...
... New knowledge about the hormonal signals like peptide signals ... processing in the brain along with the conventional neurotransmitters., ... Edinburgh report that hypothalamic neurons use the chemical signals ... peptides when are released within the brain, control different ...
Cached Medicine News:Health News:Indian And Danish Research Agencies To Work Together For Osteoporosis, 2Health News:Post-Menopausal Status May Cause Tooth Decay 2Health News:Intense Fight Against Polio In India Gets Results 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3
DSL-10-49200 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in serum. This kit requires no sample extraction or pretreatment...
RIA kit for the quantitative determination of autoantibodies to steroid 21-hydroxylase (21-OH) in serum....
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
... Increased volume for use with 4, ... and V-shaped bottom permits withdrawal of nearly ... lips to dispose of excess solution. Made ... Non-sterile. Dimensions: 78 mm W x 152 ...
Medicine Products: